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As the role of monocytes and macrophages in a range of diseases including infectious disease, inﬂammatory diseases, cancer,
and atherosclerosis is better understood, strategies to target these cell types are of growing importance both scientiﬁcally and
therapeutically. As particulate carriers, liposomes naturally target cells of the mononuclear phagocytic system (MPS), particularly
macrophages. Loading drugs into liposomes can therefore oﬀer an eﬃcient means of drug targeting to MPS cells. Physicochemical
properties including size, charge, and lipid composition can have a very signiﬁcant eﬀect on the eﬃciency with which liposomes
target MPS cells. Small, negatively charged liposomes appear to target macrophages most eﬃciently by interaction with scavenger
receptors on the macrophage cell surface. MPS cells express a range of receptors including scavenger receptors, integrins, mannose
receptors, and Fc-receptors that can be targeted by the addition of ligands to liposome surfaces. These ligands include peptides,
antibodies, and lectins and have the advantages of increasing target speciﬁcity and avoiding the need for cationic lipids to trigger
intracellular delivery. The goal for targeting monocytes/macrophages using liposomes includes not only drug delivery but also
potentially a role in cell ablation and cell activation for the treatment of conditions including cancer, atherosclerosis, HIV, and
chronic inﬂammation.
1.Introduction
Mononuclear phagocytes such as monocytes, macrophages,
and dendritic cells are intrinsically involved in innate
immunity. As the designation denotes, the chief role of these
cells is phagocytosis whereby cells will engulf and destroy
apoptotic cells, pathogens, and other targets. This occurs
either through employing opsonin receptor-dependent
mechanisms via complement- and Fc-receptors, or opsonin
receptor-independentmechanismsvialectin-receptors,scav-
enger receptors, stearylamine receptors or CD14 [1].
Due to its pivotal role in inﬂammation, the mononuclear
phagocytic system (MPS) is an important target for drug
delivery to treat disease. For certain diseases such as chronic
obstructive pulmonary disease (COPD), asthma, atheroscle-
rosis, and cancer [2–4] and for pathogenic infections includ-
ing tuberculosis [5], human immunodeﬁciency virus (HIV),
and Leishmaniasis [6], the inﬂammatory process is a key
driver of both disease progression as well as pathogenesis.
Thus strategies aimed at targeting the MPS are highly
attractive. In general however these cells are reputed to be
diﬃcult targets [7], particularly where intracellular delivery
of the active is required such as for gene delivery [8].
Thereforethedevelopmentofdeliverysystemsthatcantarget
monocytes/macrophages intracellularly is crucial and could
potentially open up new treatment paradigms for a range of
diseases.
Liposomes are the most widely investigated delivery sys-
tem for phagocyte-targeted therapies providing advantages
suchaslowimmunogenicity,biocompatibility,cellspeciﬁcity
and drug protection. However, there are also shortcomings
such as poor scale-up, cost, short shelf life, and in some
cases toxicity and oﬀ target eﬀects. Parenterally administered
liposomes are naturally cleared by the MPS. Liposomal
delivery systems targeting other cell types outside the MPS
are modiﬁed to evade phagocytosis; for example, “stealth
liposomes” include poly-ethylene-glycol (PEG) into their
formulations to shield the liposomes from the MPS and2 Journal of Drug Delivery
increase their circulatory lifespan [9]. Consequently, numer-
ous studies have been carried out to develop formulations
that avoid monocyte/macrophage clearance, the corollary
of which is that there is now greater knowledge of the
mechanisms of binding and uptake that can be harnessed for
drug targeting to monocyte/macrophage cells.
2. MonocytesandMacrophages
Cell origin, lineage, and function in the MPS are complex
and remain under considerable investigation. In essence,
monocytes diﬀerentiate from hematopoietic stem cells,
speciﬁcally granulocyte/macrophage progenitors in the bone
marrow and enter the periphery as circulating monocytes.
Various microenvironmental cues determine monocyte fate
which can lead to diﬀerentiation into macrophage and
dendritic cells [10]. However monocytes are not simply
macrophage and dendritic cell precursors but are also
immune eﬀector cells [11].
Under inﬂammatory conditions, circulating monocytes
can be recruited to the site of infection or injury, and once
there, diﬀerentiate. However under steady state conditions,
local proliferation maintains resident macrophages in sites
such as the lungs and liver. Macrophages (M∅s) are central
players in the development, progression, and resolution of
inﬂammation [12]. They are polarized following activation
i n t oc l a s s i c( o rM 1 )a n da l t e r n a t i v e( o rM 2 )m a c r o p h a g e s
[13–15].M1macrophagesareactivatedinresponsetomicro-
bial products such as lipopolysaccharide (LPS) or cytokines
like interferon-γ (IFN-γ) and tumour necrosis factor α
(TNFα) and are characterized by a strong propensity to
presentantigen.Inapolarizedresponse,M1cellsarethought
to kill intracellular microorganisms and produce abundant
proinﬂammatory cytokines such as TNF-α, interleukin (IL)-
12, IL-23, and proinﬂammatory mediators like nitric oxide
(NO) and reactive oxygen intermediates (ROI).
On the other hand, M2 macrophages are promoted
by various signals such as IL-4, IL-13, glucocorticoids,
IL-10, immune complexes and some pathogen-associated
molecular patterns (PAMPs) that elicit diﬀerent M2 forms
(M2a, b and c). They function in inﬂammation resolution
and tissue remodelling. Pathogen Recognition Receptors
(PRRs) have evolved to recognise conserved molecular-
associated molecular patterns (PAMPS) from pathogens,
such as lipopolysaccharide or bacterial DNA motifs. The
Toll-like receptors (TLRs) are one such family whose ligands
have generated much excitement over the last decade as
immunostimulatory adjuvants in vaccine development [16].
Engagement of TLRs by their cognate ligands will activate
antigen presenting cells, stimulate cytokine secretion that
regulates the adaptive immune response, and promote up
regulation of costimulatory molecules in order to improve
antigen presentation to T cells. Thus incorporation of TLR
ligands or immunomodulatory moieties into liposomes has
been a strategy for improving eﬃcacy of both vaccine
development and drug targeting [17]. For example, as
TLR ligands have been shown to activate macrophages and
dendritic cells and enhance antigen-speciﬁc T cell responses,
then enhanced uptake of PAMP-coated liposomes into these
cells would be expected. However, whilst TLR ligands and
PAMPs in general can increase liposome uptake, their ability
to stimulate and activate macrophages and enhance antigen-
speciﬁc T cell activation and immune reactivity would
suggest that their potential inﬂammatory properties may be
an issue for general use in targeting strategies [18]. In this
respect other target receptors such as the scavenger receptors
a n dm a n n o s er e c e p t o r sm a yp r o v em o r ea p p r o p r i a t e .
In addition Tumour-Associated Macrophages (TAMs)
areanM2-likemacrophagepopulationthatpromotetumour
growthviaangiogenesisandmetastasis,atleastinpart,bythe
release of proangiogenic factors including vascular endothe-
lial growth factor (VEGF) and matrix metalloproteinases
[19]. Thus targeting strategies aimed at discriminating
against M1 and M2 macrophages may be very attractive for
cancer chemotherapy in the future [20]. With respect to
cancer therapeutics, dendritic cells are major antigen pre-
sentingcellsthatplayimportantrolesincancerdetectionand
eliminationthroughtheactivationof Tcells,andinterestlies
in targeting these cells for cancer immunotherapies [21].
3.Liposomal Drug Targeting
Liposome drug delivery systems harness the physiological
role of these cells to provide speciﬁc targeting and enhance
drug eﬃcacy. Mononuclear phagocytes play major roles in
metabolism such as cholesterol and bilirubin metabolism
and pathogen clearance [12]. Hence, cell surface receptors
areexpressed, forexample, scavengerreceptorsthatallowthe
identiﬁcation and uptake of materials which can be targeted
for drug delivery. Targeting of liposomes to monocytes and
macrophages can be achieved by modifying lipid composi-
tion to control physicochemical properties such as size and
charge and by the inclusion of surface ligands including
proteins, peptides, antibodies, polysaccharides, glycolipids,
glycoproteins, and lectins (Figure 1 and Table 1).
3.1. Physicochemical Properties. Speciﬁc liposome properties
have been shown to facilitate uptake into monocytes and
macrophages and are a simple and eﬀective means of
targeting these cells.
3.1.1. Liposome Size. Recently, a detailed study by Epstein-
Barash et al. compared the eﬀect of liposome size and charge
on the bioactivity of liposomal bisphosphonates in a wide
range of cell types in vitro including monocyte/macrophage
cell lines (THP-1, J774, and RAW 264 cells) and primary
cells (neutrophils, monocytes, kupﬀer cells, endothelial cells,
and smooth muscle cells) and in vivo [24]. Liposomes
ranged in size from 50 to 800nm in diameter and were
composed of lipids with neutral, positive, or negative
charge. It was concluded that small (85nm) negatively
charged liposomes composed of neutral 1,2-distearoyl-
sn-glycero-3-phosphocholine (DSPC), anionic distearoyl-
phophatidylglycerol(DSPG),andcholesterolatamolarratio
3:1:2 were optimum for internalisation by MPS cells while
large and positively charged liposomes induced cytokine
activation and toxicity [24, 38].Journal of Drug Delivery 3
Table 1: Examples of therapeutic applications using monocyte/macrophage-targeted liposomes.
Ligand Active Disease Reference
Anionic lipids
Dexamethasone Atherosclerosis [22]
SLPI Inﬂammatory lung disease [23]
Bisphosphonates Restnosis [24]
Rifampicin Tuberculosis [25]
Dideoxycytidine-5 -triphosphate HIV [26]
Clarithromycin Mycobacterium avium infection [27]
Peptides
Muramyl tripeptide (MTP) MTP-phosphotidylethanolamine Osteosarcoma [28]
Arg-Gly-Asp (RGD) Diclofenac sodium (model drug) Cerebrovascular disease [29]
Antibodies
Anti-VCAM-1 Prostaglandins Atherosclerosis [30]
Anti-CC52 — Colon Cancer [31]
Anti-CC531 — Colon Adenocarcinoma [32]
Anti-CD11c/DEC-205 tumour antigen (OVA) Cancer [21]
Lectins
Mann-C4-Chol Dexamethasone palmitate Inﬂammatory lung disease [33]
Man2DOG — — [34]
Aminophenyl-α-D-mannopyranoside Doxorubicin Experimental visceral leishmaniasis [6]
Ciproﬂoxacin Respiratory infection [5]
Man3-DPPE OVA [35]
— Gastric cancer [36]
Other Ligands
Maleylated bovine serum albumin (MBSA) [25]
O-steroly amylopectin (O-SAP) [25]
Fibronectin [37]
Galactosyl [37]
While greater uptake of small liposomes (<100nm) by
MPS cells has been reported in the literature [37], many
other studies have shown liposome uptake by MPS cells
to be improved with increased size [39–41]. Optimal size
therefore is likely to be dependent on multiple factors
including the target cell and speciﬁc properties of the
liposome formulation, for example, receptor mediated or
nonreceptor mediated uptake. Additionally in vitro results
often diﬀer from in vivo ﬁndings [24, 40]. Particularly when
administered parentally, liposomes will interact with various
circulatory components and are then cleared by hepatocytes
in vivo [40, 42].
3.1.2. Liposome Charge. Cationic liposomes are associated
with eﬃcient cellular delivery of drug cargoes and routinely
applied for in vitro gene delivery [43]. Electrostatic interac-
tions between positively charged liposomes and the nega-
tively charged cell membranes and cell surface proteoglycans
[44] facilitate cell uptake. Unfortunately, cationic liposomes
can cause cytotoxicity limiting their safety for clinical
use [45]. In RAW264.7 macrophages cationic liposomes
containing stearylamine (SA) have previously been shown to
induce apoptosis through mitochondrial pathways generat-
ing reactive oxygen species (ROS), releasing cytochrome c,
caspase-3 and -8 and more recently activating protein kinase
C( P K C )δ possibly by cell surface proteoglycan interaction
[38, 46–48]. Consequently interest for drug delivery has
turned to neutral and anionic liposomes.
Negativelychargedlipidssuchasphosphatidylserine(PS)
and phosphatidylglycerol (PG) are preferentially recognised
by macrophages [37]. Studies comparing phosphotidyl-
choline (PC; neutral) and PS-composed liposomes have
establishednegativeliposomeformulationstohaveenhanced
macrophage internalisation [49]. Additionally, studies by us
to quantify this diﬀerence have found a 5.3-fold increase in
theassociationofnegativelycharged1,2-dioleoyl-sn-glycero-
3-phospho-L-serine (DOPS):Cholesterol liposomes with a
macrophage cell model, diﬀerentiated THP-1 cells, com-
pared to neutral 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC):Cholesterol liposomes (Figure 2)a ne ﬀect which
was also seen in vivo [50]. Negative charge can also be
achieved by the incorporation of dicetylphosphate (DCP)
[25, 40]. Vyas et al. showed a 3.4-fold increase in rifampicin
lung retention in rats when rifampicin was encapsulated
in negatively charged DCP, PC, and cholesterol-composed
liposomes and a 1.3-fold increase when encapsulated in the
correspondingneutralliposomescomparedtofreedrugafter
aerosol administration [25].4 Journal of Drug Delivery
Pathogen
Immunoliposome
Anionic liposome
Macrophage
Scavenger receptors
Lectin receptors
Fc receptors
Integrins
Mannosylated liposome
Peptide coated liposome
“Trojan liposomes”
Figure 1: Summary of liposomal targeting strategies to macrophages.
The composition of the inner membrane leaﬂet of
eukaryotic cells [1] consists of PS and phosphatidyletha-
nolamine (PE) with an outer layer of PC and sphingomyelin
(SM) [51, 52]. In an apoptotic or necrotic event, PS will be
exposed on the outer cell surface, and monocytic phago-
cytosis is induced. It is believed that PS targets scavenger
receptors (SRs) on macrophages (Figure 1) but there may
alsobereceptorsspeciﬁcforPSrecognition.MoreoverPScan
activate complement and associate with plasma apolipopro-
teins such as ApoE promoting phagocytosis by macrophages
[53]. There are six classes of SRs with A, B, and D as the most
likely participants in liposome recognition [53]. However,
not all phagocytes have the same aﬃnity for these anionic
lipids. According to Foged et al., PS and PG liposomes were
found to have minimal association with human monocyte-
and bone marrow-derived dendritic cells [54].
In addition PS is a non-bilayer lipid (along with
phosphatidylethanolamine; PE) which is frequently used in
the development of pH-sensitive and fusogenic liposomes
promoting intracellular drug delivery [51]. For instance,
liposomes composed of DOPE and PS have been assessed as
pH-sensitive carriers of plasmid DNA to RAW 264.7 alveolar
macrophages [55]. Recently Andreakos et al. developed a
novel amphoteric liposome for the delivery of antisense
oligonucleotides to sites of inﬂammation in experimental
arthritis [56]. The novel formulation known as Nov038 is
cationic at low pH and anionic at neutral pH, facilitating
complexation to nucleic acids and avoiding nonspeciﬁc
blood interactions, respectively. The group reported targeted
delivery to sites of inﬂammation as well as blood, liver,
spleen, and inguinal lymph node mononuclear cells. In
addition, Nov038 administration was well tolerated with
eﬃcient antisense oligonucleotide delivery in vivo.
3.2. Ligands. In addition to controlling the physicochemical
properties of liposomes to enhance targeting, ligands canJournal of Drug Delivery 5
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Figure 2: Uptake of neutral (DOPC:Chol 7:3) and anionic
(DOPS:Chol7:3)liposomesbydiﬀerentiated THP-1 cells after 2
hours (n = 6 ±SEM) ∗P<. 05; ∗∗P<. 001.
be incorporated into liposome formulations to speciﬁcally
target monocytes, macrophages, and dendritic cells. Using
a ligand targeting strategy for liposome drug delivery has
the advantages of potentially increasing target speciﬁcity and
avoiding the need for cationic lipids to trigger intracellular
delivery. A multitude of ligands are currently being assessed
including peptides, antibodies, proteins, polysaccharides,
glycolipids, glycoproteins, and lectins which make use of
mononuclear phagocytes characteristic receptor expression
and phagocytic innate processes (Figure 1 and Table 1). Here
we will brieﬂy look at three of the most commonly studied
systems peptide, antibody, and lectin directed delivery.
3.2.1. Peptides. Cell targeting peptides (CTPs) and cell
penetrating peptides (CPPs) have been conjugated to lipo-
somes to improve cell-speciﬁc targeting and cell uptake,
respectively, to a range of cell types [57]. Peptide sequences
such as GGPNLTGRW (GGP-peptide) have been shown
to selectively associate with neutrophils and monocytes
[58, 59]. GGP-peptide-coated liposomes, with 500 external
ligands per liposome, show 30.9 times greater association
to monocytes than uncoated liposomes [58]. Arg-Gly-Asp
(RGD) peptide has also been incorporated into liposome
formulations to target integrin receptors expressed by
monocytes [29, 60, 61]( Figure 1). Magnetic RGD-coated
liposomes achieved an increase of approximately 15% drug
recovery from monocytes and neutrophils compared to
uncoated magnetic liposomes [29].
3.2.2. Antibodies. Immunoliposomes are liposomes coupled
with antibodies which can be used to target cell-speciﬁc
antigens. In the case of phagocyte targeting, the use of
nonspeciﬁc and monoclonal antibodies can lead to liposome
opsonisation and uptake by macrophages. In vivo liposomes
interact with a wide variety of serum proteins including
immunoglobulins, apolipoproteins, and complement pro-
teins [42, 53] and may also activate complement leading to
enhanced uptake by the MPS. However, protein interaction,
complement activation, and opsonisation depend greatly on
the physicochemical properties of the liposomes such as size,
surface charge, cholesterol content, and lipid composition
[42, 53]. For example, some studies have reported comple-
ment activation to be greater with increasing liposome size
[53] although observed activation has not always been of
signiﬁcance [24].
Immunoglobulins (Igs) are recognised by Fc receptors
on the surface of phagocytic cells which are involved in
phagocytosis as well as antigen presentation [21]( Figure 1).
Interest has focused on the FcγRI receptor as a target which
recognises IgG and is expressed by monocytes, macrophages,
activated neutrophils, and DCs [21]. Opsonisation is gen-
erally Fc-receptor mediated and has previously been shown
to signiﬁcantly enhance liposome uptake by monocytes and
macrophages [32]. Opsonisation of non-immunoliposomes
by immunoglobulins, for example, IgM and IgG, can also
occur in vivo leading to enhanced uptake by macrophages
[53].
Antibodies havebeencoupledtothesurfaceofliposomes
or distally via their Fc-region to liposome-attached PEG
[31, 32]. Koning et al. showed increased Kupﬀer cell uptake
withgreaterantibody surfacedensity[31,32].Dendritic cells
have been targeted with histidine-tagged antibody fragments
attached to a novel chelator lipid, 3(nitrilotriacetic acid)-
ditetradecylamine (NTA3-DTDA), incorporated into stealth
liposomes via the DC receptors DEC-205 and CD11c [21].
3.2.3.Lectins. Immunecellsincludingalveolarmacrophages,
peritoneal macrophages, monocyte-derived dendritic cells,
and Kupﬀer cells constitutively express high levels of the
mannose receptor (MR). Macrophages and DCs can there-
fore be targeted via mannosylated nanoparticles (Figure 1).
The MR is a C-type lectin 175-kD type I transmembrane
protein [62, 63] whose ligands possess a terminal nonreduc-
ing sugar such as mannose, glucose, N-acetylglucosamine,
and fucose [64, 65]. These receptors play numerous roles in
immune function including antigenic recognition, endocy-
tosis, and antigen presentation, and are critically involved
in homeostatic maintenance, inﬂammation and immune
responses [66, 67]. Hence MR can identify and engulf
pathogens such as Mycobacterium tuberculosis and Leishma-
nia donovani via surface sugar antigens.
It should be noted that there are a wide variety of lectins
with mannose aﬃnity including MR, dendritic cell-speciﬁc
intercellularadhesionmolecule-3(DC-SIGN)andEndo180,
and many mannose receptor expressing cells but expression
andrecognition proﬁlesdiﬀerbetween celltypes [66].This is
particularly evident during inﬂammation where expression
ofMRisalteredinDCs[68].Herewewillfocusonliposomes
designed speciﬁcally for macrophage MR recognition (a
receptor that is not expressed by circulating monocytes).
Mannosylated liposomes have repeatedly been shown
to preferentially target macrophages and DCs attaining
enhanced cellular uptake both in vitro and in vivo with better
in vitro/in vivo correlation than for nonligand containing
liposomes[5,6,33–36,41,49,66,69–76].Mannosylationhas
been achieved by the incorporation of ligands such as alkyl
mannosides [70], Cholesten-5-yloxy-N-(4-((1-imino-2-α-
thioglycosylethyl)amino)butyl)formamide(Mann-C4-Chol)
[33, 74, 75, 77], Mann-His-C4-Chol [77], Man2DOG
[34], 4-aminophenyl-a-D-mannopyranoside [5, 69], and6 Journal of Drug Delivery
manntriose (Man3)-DPPE [35, 36, 71] into the liposome
formulations or by liposome coating with p-aminophenyl-
α-D-mannopyranoside [6]. We have prepared a range of
mannosylated liposome, and quantiﬁed the increase in cell
association with a macrophage-like cell model, diﬀerentiated
THP-1 cells. Mannosylated liposomes signiﬁcantly increased
liposome association with the macrophages compared to
uncoated controls (Figure 3)[ 78].
Over the past decade Hasida and colleagues have led
the way in the development of mannosylated liposomes
targeted to macrophages and DCs for the delivery of anti-
inﬂammatory agents dexamethasone palmitate [33]a n d
Nuclear factor κ-B (NFκB) decoy and anticancer agents CpG
oligonucleotidesandDNA[79].Intratracheallyadministered
Man-C4-Chol liposomes were shown to be preferentially
taken up by alveolar macrophages which was mediated via
MR endocytosis as revealed by inhibition studies. Manno-
sylation and the extent of this mannosylation signiﬁcantly
improved liposome internalisation by macrophages [72].
The ability of these liposomes to eﬃciently deliver their
load has been the focus of a more recent study in which
the use of bubble liposomes and ultrasound in combination
with mannosylated liposomes to deliver plasmid DNA to
macrophages and dendritic cells was assessed [73]. Signiﬁ-
cant enhancement of transfection eﬃciencies was reported
using these formulations in comparison to plasmid DNA
alone and unmodiﬁed liposomes.
4. Liposome Drug Deliveryfor
the Treatment of Disease
4.1. Infection. A major role of mononuclear phagocytes is
the capture and presentation of pathogenic antigens. Certain
pathogensarecapableofsurvivingmacrophagephagocytosis
suchasBrucellaspecies[80],HIV[81,82],andmycobacteria
[83]. As a result viruses and bacteria can be harboured
and proliferate within these cells. Macrophages can better
withstand the cytopathic eﬀects of HIV than T cells [81, 82],
while some pathogens such as certain brucella species impair
the apoptotic ability of macrophages and monocytes [80],
and subsequently survival time of the pathogen-infected cell
is extended. As these cells can cross tissue barriers such as the
blood brain barrier (BBB), the virus can spread unrestricted
[81].
The ability of these pathogens to infect, evade the host’s
phagocytic mechanisms, and replicate creating pathogen
reservoirs that can disseminate throughout the body stresses
the importance of the development of targeted therapeutics
to macrophages and other phagocytic cells. Liposome deliv-
ery to these pathogen reservoirs has received some attention
[84, 85]. Targeting strategies studied to-date include the use
of negatively charged liposomes containing PG [26, 27],
sterically stabilized immunoliposomes incorporating surface
anti-HLA-DR antibodies [86], tuftsin [87], galactosylated
[88], and mannosylated [89]l i p o s o m e s( Table 1). Overall in
these studies, the liposome encapsulation of anti-infectives
was generally found to decrease cellular toxicity, modify
pharmacokinetics, and improve targeting thereby enhancing
the overall eﬃcacy of the anti-infective agents.
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Figure 3: Uptake of uncoated and mannosylated liposomes by
macrophage like diﬀerentiated THP-1 cells after 2 hours [78]. (n =
6 ±SEM) ∗P<. 05; ∗∗P<. 001.
4.2. Inﬂammation and Cancer. Mononuclear phagocytes are
recruited to sites of injury and cancer, and these sites become
areas with a high macrophage presence. As inﬂammatory
cells, macrophages release proinﬂammatory cytokines such
as TNFα further increasing inﬂammation. This process can
be utilized in two ways for drug targeting. Firstly, cells can
be targeted and activated to bestow tumour suppressive
propertiesforcancertherapy[7].Secondly,forinﬂammatory
disease, the inﬂammatory response can be reduced using
anti-inﬂammatory drugs or cell killing to deplete mono-
cyte/macrophage cell populations.
Activation of macrophages is a means of augmenting
antitumor immune responses [4] by the induction of
proinﬂammatory mediators such as TNFα, IL-8, and nitric
oxide (NO) [28]. For instance liposomal delivery of hexade-
cylphosphocholine [2], JBT3002, a synthetic lipopeptide [3],
the tetrapeptide (Thr-Lys-Pro-Arg) tuftsin, and muramyl
tripeptide phosphatidylethanolamine (MTP-PE) [28]h a s
been investigated. MTP-PE is a synthetic glycopeptide that
canactivatemonocytesandmacrophagespromotingtumour
regression [28]. A liposomal MTP-PE formulation (L-MTP-
PE; mifamurtide) is currently in clinical trials for high risk
osteosarcoma.
Bisphosphonates, for example, clodronate and alen-
dronate, are extensively used in the treatment of osteo-
porosis but have also shown the ability to induce apop-
tosis in monocytes and macrophages. Interest lies in their
therapeutic potential for inﬂammatory disorders. To date
a range of potential therapies for inﬂammatory related
conditions including nerve injury-associated hyperalgesia
[90], endometriosis [91], lung cancer cell metastasis [92],
arthritis [93], restinosis [24, 94], and hyperlipidemia [95]
havebeenassessedusingliposome-mediatedbisphosphonate
delivery. Other inducers of macrophage apoptosis have been
investigated such as propamidine [96] and locally admin-
istered inhibitors such as cycloheximide for atherosclerosis
treatment [95].
4.3. Cardiovascular Disease. The role of monocytes/macro-
phages in the development of atherosclerosis is undisputed
[97, 98]. Following endothelial cell damage, monocytesJournal of Drug Delivery 7
are recruited to the site via the release of chemokines.
Following extravasation to the intima, recruited and resident
macrophages play a critical role in the development of the
atherosclerotic plaque via the scavenging of oxidised LDL
and the ultimate diﬀerentiation into foam cells which form
theatherosceloticplaquecore.TheglycoproteinCD36iscen-
traltothisprocess.CD36isamemberofthescavengerrecep-
tor class B which is expressed on macrophages/monocytes,
platelets, and endothelial cells. Its importance in atheroscle-
rosis has clearly been established through studies in the
ApoE-deﬁcient mice, demonstrating that inactivation of
CD36 results in substantially reduced lesion size. Therefore
targetingofCD36-expressingmacrophagesinatherosclerotic
lesions using a ligand, for example, the growth peptide
Hexarelin, can be envisaged to have a dual eﬀect—the
delivery of therapeutic agents to the lesion and the neu-
tralisation of LDL uptake. Hexarelin, a member of the
hexapeptide growth hormone-releasing peptides (GHRPs),
binds to CD36 receptors [99].
Investigations into liposome targeting to atherosclerotic
lesions have looked at their potential for delivery of con-
trast agents for diagnostic imaging [100, 101]a n da n t i -
inﬂammatory drugs for therapy development. For instance,
Chono and colleagues have investigated liposomal delivery
to macrophages as a therapeutic approach to atherosclerosis
in several studies [22, 40, 102] using anionic liposomes
consisting of egg yolk phosphotidylcholine (PC), cholesterol,
and DCP at a molar ratio 7:2:1 and sized to 70, 200 and
500nm. In vitro uptake by macrophages and foam cells
was improved with increasing particle size [22, 40, 102];
however, in vivo, optimal aortic delivery in atherogenic
mice was achieved using 200nm liposomes. In addition,
various studies have shown signiﬁcant antiatherosclerotic
eﬀects in vivo by liposomal delivery of dexamethasone,
cyclopentenone prostaglandins, and serum amyloid A (SAA)
peptide fragments [22, 30, 103].
4.4. Cerebral Ischemia and Stroke. The role of the innate
immune system and inﬁltrating macrophages and resident
microglia in cerebral ischemia is currently an area of
intenseinvestigation.Inﬂammation,beitsterileorinfection-
induced, plays an important part in cerebral ischemic
injury. Interestingly CD36 is upregulated in a number of
inﬂammatory and pathological conditions, such as cerebral
ischemia and stroke. Both CD36 and TLR2 are upregulated
on microglia and inﬁltrating macrophages under ischemic
conditions and triggering either will induce a potent inﬂam-
matory response [104, 105]. One study investigated the use
of inﬁltrating macrophages to deliver a systemically admin-
istered gene therapy in stroke [106]. Plasmids expressing
enhanced green ﬂuorescent protein (EGFP) and ﬁbroblast
growth factor-2 (FGF-2) were complexed with cationic
liposomes, administered into the femoral vein resulting in
expression of EGFP and FGF-2 in inﬁltrating macrophages
and in the cerebral infarction.
4.5. Other. There has also been some attention paid to
“Trojan monocytes” for drug delivery to the brain [107]a s
a means of delivering drugs to inaccessible sites (Figure 1).
Delivery of drugs to the brain is greatly hampered by the
extremely selective permeability of the blood brain barrier
(BBB). However, immune cells such as phagocytes can cross
this barrier. Therefore by targeting circulating mononuclear
cells with drug-loaded liposomes, this natural BBB uptake
process can be harnessed for drug delivery.
Previous studies have used RGD-liposomes [29, 60, 61]
as well as magnetic liposome formulations [29, 108]f o r
delivery to the brain via monocytes and neutrophils. Afergan
et al. prepared PG-composed liposomes for the delivery
of the neurotransmitter serotonin [109]. In vivo studies
showed localisation to the brain to be improved by liposome
encapsulation and that the delivered liposomes were intact.
FACS analysis of rabbit blood 4 hours posttreatment showed
higher uptake of liposomes by monocytes over granulocytes.
Uptake was also observed by monocytes and neutrophils in
vivo and in vitro but it was shown that monocytes were the
neurodelivery cells by an alendronate monocyte depletion
study [109]. More recently Saiyed et al. developed azi-
dothymidine 5 -triphosphate (AZTTP) containing magnetic
liposomes as a therapeutic for neuroAIDS [108]. Magnetic
nanoparticles (Fe3O4, magnetite) were encapsulated with
AZTTPinneutralliposomes,andtransmigrationofthelipo-
somes in monocytes was monitored across an in vitro BBB
model in the presence of a magnet. By magnetic liposome
endocytosis, monocytes become magnetic and responded
to magnetic ﬁelds [29]. The transmigration of magnetic
monocytes was signiﬁcantly increased in the presence of a
magnet in comparison to nonmagneticlinebreak monocytes.
A study by Matsui et al. examined the potential of
peripheral blood monocytes (PBMCs) and human peri-
toneal macrophages as drug carriers in gastric cancer [36].
Oligomannose-coated liposomes were successfully targeted
to monocytes and macrophages showing signiﬁcantly higher
uptake than bare liposomes. These liposome-loaded human
monocytes and macrophages were found to accumulate at
the disease target site micrometastases and milky spots of the
omentum in mice and ex vivo in resected human omentum.
5. Conclusion
As the role of monocytes and macrophages in a range of
diseases including infectious disease, inﬂammatory diseases,
cancer, and atherosclerosis is better understood, strategies
to target these cell types are of growing importance both
scientiﬁcally and therapeutically. Eﬃcient methods of tar-
geting these cells can facilitate eﬃcient drug delivery but
also potentially facilitate cell activation and ablation. The
properties of liposomes mean they naturally target cells of
the MPS, particularly macrophages. This natural targeting
capacity can be harnessed for drug delivery. By controlling
the liposome physicochemical properties including size,
charge, and lipid composition, natural targeting can be
further enhanced. A range of ligand-mediated strategies for
liposometargetingtoMPScellshavebeenexploredincluding
peptide-, antibody-, and lectin-coating to speciﬁcally target
drug-loaded liposomes to some of the many receptor types
expressed on macrophage and monocyte cells.8 Journal of Drug Delivery
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